Modalis Reports 2021 Financial Results and Operational Highlights Please see the link for details Modalis Reports 2021 Financial Results and Operational Highlights
Modalis Reports First Quarter 2022 Financial Results and Operational Highlights Please see the link for details Modalis Reports First Quarter 2022 Financial Results and Operational Highlights
Modalis Reports Second Quarter 2022 Financial Results and Operational Highlights Please see the link for details Modalis Reports Second Quarter 2022 Financial Results and Operational Highlights
An auto-reply confirmation e-mail has been sent to the e-mail address you entered. In the unlikely event that you do not receive an auto-reply e-mail, there may have been a mistake in the e-mail address you entered. Please check your e-mail address and contact us again using the form.
Modalis Therapeutics, Cure CMD, and Voor Sara provide an update on the **MDL-101 program**, a potential treatment for **LAMA2-related dystrophy**. The initiative is progressing toward clinical development amid growing interest from patients and families. The organizations emphasize transparency and consistency in sharing information to support the affected community.
Swiss patient organization *Emily’s Future is Now* donates funds to **Modalis**, supporting research for **LAMA2-related congenital muscular dystrophy (LAMA2-RD)**. The donation comes from a group focused on advancing treatments for this rare genetic disorder. Modalis now has additional financial backing to further its mission in the field.
Modalis Therapeutics outlines its business strategy and growth initiatives on the Tokyo Stock Exchange. The company details plans to expand its therapeutic pipeline, though specific projects or timelines are not disclosed. Investors focus on its potential in the biopharmaceutical sector amid market volatility.
Modalis Therapeutics highlights its MDL-101 drug candidate for **LAMA2 congenital muscular dystrophy (CMD)** in *LAMA2 Europe*. The company previously published related research in *Human Gene Therapy*, advancing preclinical development for this rare genetic disorder.
The FDA grants orphan drug designation to **MDL-101**, a therapy targeting **LAMA2-congenital muscular dystrophy (LAMA2-CMD)**, a rare pediatric disease. The designation supports expedited development for conditions affecting fewer than 200,000 people in the U.S. The move follows recent regulatory recognition of MDL-101’s potential in treating this genetic disorder.